Lead Product(s): Coronavirus-neutralising antibodies
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
The applications were based on results from the Phase 3 CheckMate -9LA trial. In October 2019, the company announced the trial met its primary endpoint.